$1.00
1.18% today
Nasdaq, Feb 05, 03:56 pm CET
ISIN
US23283X2062
Symbol
CTSO

CytoSorbents Corporation Stock price

$0.99
-0.05 4.97% 1M
-0.07 6.76% 6M
+0.08 8.60% YTD
-0.00 0.15% 1Y
-2.65 72.85% 3Y
-4.26 81.18% 5Y
-6.98 87.60% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.01 1.17%
ISIN
US23283X2062
Symbol
CTSO
Sector

Key metrics

Market capitalization $54.19m
Enterprise Value $75.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.00
P/S ratio (TTM) P/S ratio 1.44
P/B ratio (TTM) P/B ratio 4.14
Revenue growth (TTM) Revenue growth 1.80%
Revenue (TTM) Revenue $37.74m
EBIT (operating result TTM) EBIT $-21.59m
Free Cash Flow (TTM) Free Cash Flow $-18.80m
Cash position $5.69m
EPS (TTM) EPS $-0.36
P/E forward negative
P/S forward 1.38
EV/Sales forward 1.92
Short interest 3.09%
Show more

Is CytoSorbents Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

CytoSorbents Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a CytoSorbents Corporation forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a CytoSorbents Corporation forecast:

Buy
50%
Hold
50%

Financial data from CytoSorbents Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
38 38
2% 2%
100%
- Direct Costs 14 14
1% 1%
37%
24 24
4% 4%
63%
- Selling and Administrative Expenses 33 33
1% 1%
89%
- Research and Development Expense 9.72 9.72
35% 35%
26%
-19 -19
25% 25%
-52%
- Depreciation and Amortization 2.11 2.11
40% 40%
6%
EBIT (Operating Income) EBIT -22 -22
21% 21%
-57%
Net Profit -19 -19
20% 20%
-49%

In millions USD.

Don't miss a Thing! We will send you all news about CytoSorbents Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytoSorbents Corporation Stock News

Neutral
GlobeNewsWire
about one month ago
Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week PRINCETON, N.J.
Neutral
GlobeNewsWire
about 2 months ago
PRINCETON, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that management will host in-person investors meetings in San Francisco alongside the 43rd Annual J.P.
Neutral
GlobeNewsWire
3 months ago
PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to anno...
More CytoSorbents Corporation News

Company Profile

CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio include CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

Head office United States
CEO Phillip Chan
Employees 186
Founded 2002
Website cytosorbents.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today